Early Phase 1 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with stage III melanoma that has spread to one or more lymph nodes in a way that can be measured on scans, and where a biopsy or surgery is possible
- People whose treating doctor has determined they have stage III or stage IV melanoma where tissue samples (biopsies) can be taken more than once over time — including some people with a type of spread called in-transit metastasis, after a surgeon has been consulted
- People whose cancer can be safely biopsied multiple times, and who are willing to have repeat biopsies and blood tests as required by the trial
- People aged 18 or older
- People who are generally well and able to carry out normal daily activities (this is measured using a standard scale called ECOG, scores 0 or 1)
- People whose heart, liver, kidneys, and bone marrow are functioning normally
Who may not be able to join:
- People who are currently taking part in another clinical trial involving an experimental treatment
- People who have a known active autoimmune disease (a condition where the immune system attacks the body's own tissues)
- People who have previously been treated with certain types of immunotherapy drugs that target pathways known as CTLA-4 or PD-1/PD-L1
- People who need to take medications that suppress the immune system, including high-dose steroid medications, for an ongoing medical condition
- People who have been experiencing frequent diarrhoea (more than 4 bowel movements per day) that has not improved with medical treatment in the two weeks before starting the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anthony Olszanski, MD, Fox Chase Cancer Center
Phone: 2152141676
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.